Artificial Intelligence is helping some of the top pharmaceutical companies to process phenotypic, imaging, drug and genomic data sets, while allowing the researchers to integrate rapid analytics and machine learning capabilities into existing business processes to improve health care, enhance discoveries, gain insight into business and enable fast data-driven decisions that can help save the pharma industry billions of dollars within the next few years.
As it is nearly impossible to miss the build-up around artificial intelligence and its potential to transform business performance especially for the pharmaceutical industry across the world, MediSER Events brings to you one of the most awaited international conferences- AI Impact on Future Pharma.
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods. This was recently demonstrated by the results of the Critical Assessment of Structure Prediction (CASP) contest hosted by the Protein Structure Prediction Center, sponsored by the U.S. National Institute of General Medical Sciences I (NIH/NIGMS). The AI IMPACT ON FUTURE PHARMA will be providing experts involved in pharmaceutical and developing AI with a common platform to share their concerns and find solutions to the challenges that the new age technology is posing.
According to experts, the fundamental shift in drug discovery and artificial Intelligence holds the key to bringing the pharma industry into the 21st Century. Artificial Intelligence and machine learning, in particular, present the pharmaceutical industry with a real opportunity to do R&D differently, so that it can operate more efficiently and substantially improve success at the early stages of drug development.
The long-term benefits of this will mean that the vast resources and money used to develop drugs in the current process will be deployed more effectively to give not only a better return on the investment but also a substantial increase in the delivery of new medicines for serious diseases.
The pharma is currently spending well over $1 billion per drug from its inception to picking up the protein target, developing assays, screening molecules, safety tests on animals and then human testing which takes 1 to 10 years’ time, even when years of research is already available for discovering new drugs.
However, with AI the pharmaceutical companies can introduce machines that can learn and help their researchers get hands on the huge variety of biomedical databases and all of the scientific knowledge which is already available and enhance their ability to correlate, assimilate and connect all this data. The AI can produce usable knowledge that can accelerate drug discovery.
The pharmaceuticals companies that are already exploring the benefits of AI have only just scratched the surface of machine learning, but have still managed to get meaningful insights into diseases and identifying promising targets.
The AI technology when further evolved can lead to unparalleled advances into a much broader chemical space and help in discovering wider and more varied chemical palette to better enable the pharmaceuticals to pick the best molecules for drug discovery.
MediSER Events is one of the leading international events organising company based in the USA that has been bridging the gap between the latest advents in the field of technology and the healthcare and pharmaceuticals. MediSER that stands for Medical Information Services provide a common platform for the experts in the field of technology and the healthcare for intellectual assimilation of the new discoveries and how these can be transformed into long term financial and operational benefits for the industry.